New drug pricing law puts cancer drugs in the spotlight

United States News News

New drug pricing law puts cancer drugs in the spotlight
United States Latest News,United States Headlines
  • 📰 axios
  • ⏱ Reading Time:
  • 68 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 30%
  • Publisher: 63%

Democrats' new drug pricing law will likely deliver a financial blow to one of the fastest-growing and most lucrative segments of the pharmaceutical industry: cancer drugs.

Democrats' new drug pricing law will likely deliver a financial blow to one of the fastest-growing and most lucrative segments of the pharmaceutical industry: cancer drugs.The drug industry argues that the new law will keep oncology treatments from reaching some patients who need them. But experts say the current system lets companies profit from developing drugs that yield only incremental advances — and that cancer drugs will still be valuable enough for companies to pursue.

But the cancer market is unique, both in terms of its recent growth trajectory and in how drugs' uses typically evolve once they’re already on the market.Research on cancer drugs after initial approval "will be gutted by this bill," Stephen Ubl, CEO of the industry trade group Pharmaceutical Research and Manufacturers of America,"It tells researchers that their successful post-approval research will quickly be subject to government price setting.

Drug companies argue the limitation on their ability to maximize a cancer drug’s revenue will mean it may not be worth it to look for new indications of the drug.that 15 fewer drugs would be introduced to the market over a 30 year period as a result of the law. Put into context, about 1,300 drugs typically would be approved over the next 30 years under current law.

"If a supplemental indication is a big enough group of cancer patients, then it will still make financial sense to seek a label expansion to those patients," Kesselheim said.Rachel SachsAnd the law may actually encourage drugmakers to focus on more truly novel products, Sachs argued. "We may not need companies to develop another inhibitor — and so, it's the case right now that pharma isn't always choosing to invest in the spaces that are the best spaces.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

axios /  🏆 302. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Gov. Newsom vetoes bill to bring drug injection sites to Oakland, SF. Did presidential aspirations play a part?Gov. Newsom vetoes bill to bring drug injection sites to Oakland, SF. Did presidential aspirations play a part?The law would have allowed drug consumption sites in Oakland and San Francisco.
Read more »

Why doctors are prescribing a cheap, well-known drug as an off-label cure for hair lossWhy doctors are prescribing a cheap, well-known drug as an off-label cure for hair lossMinoxidil is not a new drug treatment, not even for hair loss.
Read more »

Why doctors are prescribing a cheap, well-known drug as an off-label cure for hair lossWhy doctors are prescribing a cheap, well-known drug as an off-label cure for hair lossMinoxidil is not a new drug treatment, not even for hair loss.
Read more »

Why doctors are prescribing a cheap, well-known drug as an off-label cure for hair lossWhy doctors are prescribing a cheap, well-known drug as an off-label cure for hair lossMinoxidil is not a new drug treatment, not even for hair loss.
Read more »

Chart: America's surge of spending on clean energyChart: America's surge of spending on clean energy📊 America’s annual spending on clean energy has surged through the years, and this graphic from a new report helps puts new and recent energy laws into historical context. Go deeper:
Read more »



Render Time: 2025-03-11 06:27:52